Searched for
ERIS CORONA
Is Corona Remedies’ IPO a compelling bet for long-term wealth creation?Corona Remedies is set to raise ₹655.4 crore via an offer for sale. The company focuses on specialist doctors, driving faster revenue growt...- Fund X represents a 60% increase over previous $1.35 billion Fund IX closed in 2022In a landmark move, ChrysCapital has successfully garnered a staggering $2.2 billion for its latest venture, ChrysCapital X, marking a pivo...
- ChrysCapital sets sights on pharma buyout dealsChrysCapital, led by MD Kshitij Sheth, aims to acquire Indian companies in the formulation business with potential valuations of $200 milli...
- ChrysCap buys small stake in generics company La Renon for Rs 600 crIncorporated in 2007 by Pankaj Singh, La Renon is engaged in the manufacturing and marketing of branded generic formulations. ChrysCapital ...
- Total solar eclipse: North Americans celebrate with cheers, music and matrimonyNorth American skywatchers celebrated a total solar eclipse, with festive events in various locations. The eclipse brought awe and joy, wit...
- Solar Eclipse 2024: How long will the Great American Eclipse darkness last in your city?As anticipation builds for the Great American Eclipse, skygazers across the nation are gearing up for the Solar Eclipse 2024 that promises ...
- Eris: Symptoms, Vaccines and all about the new dominant Covid variant which is leading to a fresh wave in the U.S and U.KThe Eris variant, or EG.5, a dominant Covid subvariant, has surged to prominence as the most prevalent subvariant in the United States and ...
- CORONA remedies buys Sanofi India's ortho brand MyorilAhmedabad-based pharmaceutical company CORONA Remedies has acquired the muscle relaxant brand Myoril from Sanofi India for Rs234 crore. The...
- CY22 to be year of mid & smallcaps? 3 deep value ideas from G Chokkalingam"I am extremely bullish on the economy as the Tsunami of retail investors gives me a lot of confidence that CY2022 is going to be the year ...
- Go for OEMs in auto, look outside the usual in pharma: Kunj Bansal“There has been some flattishness in the non-Covid related medicine demand.”
- ChrysCap to buy 30% in Corona Remedies for Rs 670 croreChrysCap has signed a deal to acquire 20% stake from PE firm Creador, which is an existing investor, and another 10% from promoters, two pe...
Load More
